KAOLIN AND MORPHINE MIXTURE

Indications

Mechanism of action

Morphine and its metabolites act as agonists at the mu and kappa opioid receptors. The mu-opioid receptor is responsible for morphine's analgesic effects and its action on the reward pathway in the brain, primarily affecting the ventral tegmental area. Morphine-6-glucuronide, a major metabolite, is responsible for a significant portion of morphine's analgesic effect, with approximately 85% of the response attributed to it. Additionally, morphine modulates pain transmission by blocking nociceptive signals and inhibiting primary afferent nociceptors in the spinal cord.

Pharmacodynamics

Morphine binding to opioid receptors blocks the transmission of nociceptive signals, modulating pain pathways within the spinal cord. Its onset of action ranges from 6 to 30 minutes, with effects varying based on individual factors such as sex; for instance, the EC50 for analgesia is lower in women than in men. Chronic use can lead to alterations in neuroplasticity, affecting synaptic structures and potentially leading to tolerance or dependence. Morphine's analgesic effects also include respiratory depression, which is a significant risk associated with its use.

Pharmacokinetics

Morphine is absorbed through various routes, including oral and intravenous administration, with its bioavailability being significantly lower when taken orally due to first-pass metabolism. The drug is extensively metabolized in the liver, primarily to morphine-3-glucuronide and morphine-6-glucuronide. The elimination half-life of morphine ranges from 2 to 4 hours, but can be prolonged in patients with renal or hepatic impairment. Morphine is excreted mainly via the kidneys, necessitating dose adjustments in patients with renal dysfunction to prevent accumulation and increased risk of adverse effects.

Contra-indications

• Severe respiratory depression
• Acute or severe bronchial asthma
• Known or suspected gastrointestinal obstruction
• Hypersensitivity to morphine or any component of the formulation

Adverse effects

• Diarrhoea
• Gastrointestinal disturbances
• Drowsiness
• Depression
• Hypotension
• Nausea
• Vomiting
• Constipation
• Erectile dysfunction
• Visual impairment
• Tremors
• Hyperalgesia
• Seizures
• Withdrawal syndrome

Interactions

• Ritonavir may decrease morphine concentration
• Nirmatrelvir boosted with ritonavir may decrease morphine concentration
• Pitolisant may decrease morphine exposure
• Rifampicin may decrease morphine exposure

Precautions

• Caution in patients with pancreatitis
• Caution in patients with hepatic impairment
• Caution in patients with renal impairment
• Caution in patients with a history of substance use disorder
• Monitor for signs of respiratory depression
• Dose adjustments may be necessary in the elderly or those with comorbidities

Pregnancy

Use only if potential benefit outweighs risk, as morphine may affect fetal development

Breast-feeding

Use with caution; avoid if possible due to lack of information on excretion in breast milk

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Formulations

• Oral solution
• Modified-release capsules
• Injection solution
• Tablets

Indications

• Metabolic acidosis
• Acid-base imbalance
• Urinary alkalinization
• Treatment of certain poisonings
• Cardiac arrest in the context of metabolic acidosis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosages, as they depend on the clinical condition

Adults: Refer to local guidelines and BNF for specific dosing recommendations as they may vary based on clinical condition and severity. General adult dosing for bicarbonate may range from 1 to 2 mEq/kg IV initially, followed by maintenance doses as needed.

Mechanism of action

Bicarbonate acts as a buffer that neutralizes excess acids in the body. It dissociates in solution to produce bicarbonate ions (HCO3-) which can react with hydrogen ions (H+) to form carbonic acid (H2CO3), subsequently leading to the production of carbon dioxide (CO2) and water (H2O). This process helps to raise the pH of the blood and other fluids, counteracting acidosis. Bicarbonate is involved in several metabolic pathways, including the urea cycle and various biosynthetic pathways.

Pharmacodynamics

Bicarbonate's primary pharmacodynamic effect is its ability to buffer hydrogen ions, thus increasing blood pH. This is essential in conditions such as metabolic acidosis, where the body accumulates excess acid. By raising blood pH, bicarbonate can help alleviate symptoms associated with acidemia, such as fatigue, confusion, and shortness of breath. Its effects can also influence the renal and respiratory systems to regulate acid-base homeostasis.

Pharmacokinetics

Bicarbonate is rapidly absorbed from the gastrointestinal tract. It is distributed throughout the body fluids, and its effects can be seen within minutes of administration. The kidneys play a significant role in bicarbonate homeostasis by reabsorbing bicarbonate from urine and excreting hydrogen ions. The elimination half-life can vary, depending on the patient's metabolic state and renal function.

Pregnancy

Use with caution. Consult with a healthcare provider before use.

Breast-feeding

Use with caution. Consult with a healthcare provider before use.

Storage

Store in a cool, dry place away from light.

Dosage

Children: Chloroform is not indicated for pediatric use due to safety concerns and potential for toxicity. Refer to specific clinical guidelines for any related interventions or alternative agents.

Adults: Chloroform is not commonly used in clinical practice today and specific dosing recommendations should be referred to in relevant clinical guidelines or literature. It is important to note that due to its toxicity, chloroform usage is highly restricted.

Mechanism of action

Chloroform undergoes bioactivation primarily through covalent binding to lipids and proteins, particularly under anaerobic conditions with the presence of NADPH. This process is linked to the inhibition of cytochrome P450 and related mono-oxygenases, with biotransformation being mediated by phenobarbital-inducible P450 isozymes. The resultant oxidation products impair the monooxygenase system, potentially leading to protein aggregation.

Pharmacodynamics

Chloroform has a depressant effect on the central nervous system, leading to sedation and anesthesia at sufficient exposure levels. Its effect on cytochrome P450 enzymes suggests a mechanism that can alter drug metabolism and pharmacokinetics of concurrently administered medications, potentially leading to toxic accumulation or therapeutic failure.

Pharmacokinetics

Chloroform is rapidly absorbed through inhalation and dermal exposure, with distribution throughout the body, including the liver and brain. It is metabolized primarily in the liver via the cytochrome P450 system, leading to the formation of reactive intermediates. Chloroform and its metabolites are eliminated through exhalation and renal excretion, but the potential for accumulation and toxicity remains a concern.

Pregnancy

Chloroform is not recommended for use during pregnancy due to potential risks to fetal development.

Breast-feeding

Chloroform is not recommended during breastfeeding as it may be excreted in breast milk and could pose risks to the infant.

Storage

Store in a cool, dry place away from light, in a tightly sealed container.

Indications

• Acute diarrhea
• Chronic diarrhea
• Gastroenteritis
• Toxin absorption

Dosage

Children: Refer to established guidelines for specific dosing, as dosing may vary based on formulation and clinical context.

Adults: Refer to established guidelines for specific dosing, as dosing may vary based on formulation and clinical context.

Mechanism of action

Kaolin acts by adsorbing various substances within the gastrointestinal tract. It binds to toxins, bacteria, and other pathogens, which helps to prevent their absorption into the bloodstream. This action reduces the irritation of the intestinal lining and helps restore normal bowel function.

Pharmacodynamics

The pharmacodynamic effects of kaolin include its ability to absorb and retain moisture, which can help solidify feces. Its adsorbent properties may also contribute to its therapeutic effects in gastrointestinal disturbances. By binding to pathogens and toxins, kaolin may reduce inflammation and irritation in the gut.

Pharmacokinetics

Kaolin is not absorbed systemically when administered orally; it remains in the gastrointestinal tract where it exerts its effects. The elimination of kaolin occurs through fecal excretion. Its local action in the gut allows it to exert therapeutic benefits without significant systemic exposure.

Adverse effects

• Constipation
• Abdominal discomfort
• Nausea
• Vomiting

Precautions

• Use with caution in patients with gastrointestinal obstruction
• Monitor for potential constipation, especially in elderly patients

Pregnancy

Kaolin is generally considered safe during pregnancy, but it should be used under medical supervision.

Breast-feeding

Kaolin is not known to be excreted in breast milk and is considered safe during breastfeeding.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Oral suspension
• Powder

Indications

• Vision correction
• Phototherapy for skin conditions (e.g., psoriasis, eczema)
• Treatment of seasonal affective disorder (SAD)
• Circadian rhythm disorders
• Wound healing

Dosage

Children: Light therapy for paediatric patients should be approached with caution and always under professional guidance. Specific dosages will depend on the individual treatment protocol and condition being addressed.

Adults: Dosage of light therapy varies based on the condition being treated and should be tailored to individual needs, typically ranging from 15 minutes to 2 hours of exposure per day depending on the specific treatment protocol.

Mechanism of action

Light affects biological systems primarily through phototransduction, which involves the conversion of light into electrical signals within photoreceptor cells in the retina. This process initiates a cascade of biochemical reactions that ultimately lead to visual perception. In addition, specific wavelengths of light can interact with various biological molecules, triggering cellular responses such as the production of vitamin D through skin exposure to UVB radiation.

Pharmacodynamics

The pharmacodynamic effects of light are highly dependent on its wavelength and intensity. Short-wavelength blue light (around 480 nm) is known to influence circadian rhythms by affecting melatonin secretion. In therapeutic settings, light can modulate biological responses, such as promoting wound healing, reducing inflammation, and alleviating symptoms of seasonal affective disorder (SAD) through bright light therapy.

Pharmacokinetics

Light does not undergo traditional pharmacokinetic processes such as absorption, distribution, metabolism, or excretion. Instead, its effects are immediate and localized, depending on the intensity and duration of exposure. The penetration depth of light varies with wavelength; for example, UV light can penetrate the skin and affect deeper tissues, while visible light primarily affects the surface layers.

Pregnancy

There is limited data on the effects of light exposure during pregnancy. However, excessive exposure to bright light can be harmful to both the mother and the developing fetus.

Breast-feeding

Light exposure is generally considered safe while breastfeeding, but excessive exposure should be avoided to prevent potential harm to the infant.

Storage

Light should be properly controlled and managed in environments where it is used, ensuring that exposure levels are safe and effective.

Mechanism of action

Morphine-6-glucuronide is responsible for approximately 85% of the response observed by morphine administration. Morphine and its metabolites act as agonists of the mu and kappa opioid receptors. The mu-opioid receptor is integral to morphine's effects on the ventral tegmental area of the brain. Morphine's activation of the reward pathway is mediated by agonism of the delta-opioid receptor in the nucleus accumbens, while modification of the respiratory system and addiction disorder are mediated by agonism of the mu-opioid receptor. Visual analysis of the direct electroencephalograph has revealed that morphine /slowed/ the predominant frequency and /increased/ high-voltage delta activity.

Pharmacodynamics

Morphine binding to opioid receptors blocks transmission of nociceptive signals, signals pain-modulating neurons in the spinal cord, and inhibits primary afferent nociceptors to the dorsal horn sensory projection cells. Morphine has a time to onset of 6-30 minutes. Excess consumption of morphine and other opioids can lead to changes in synaptic neuroplasticity, including changes in neuron density, changes at postsynaptic sites, and changes at dendritic terminals. Intravenous morphine's analgesic effect is sex dependent. The EC₅₀ in men is 76ng/mL and in women is 22ng/mL. Morphine-6-glucuronide is 22 times less potent than morphine in eliciting pupil constriction.

Mechanism of action

The feasibility of an oxygen-independent mechanism of chloroform bioactivation was indicated by the covalent binding to lipid and protein occurring in anaerobic incubations of chloroform and microsomes in the presence of NADPH. Under these conditions, the loss of cytochrome p450 and the inhibition of related mono-oxygenases were also observed. The chloroform anoxic biotransformation was negligible in uninduced microsomes and seemed to be catalyzed mainly by phenobarbital-inducible p450 isozymes. Biotransformation could also be supported by NADH as the source of reducing equivalents. Anaerobic metabolism of chloroform led to decreased levels of the main phenobarbital-induced p450 isozymes even at low chloroform concentration, and did not affect benzo(a)pyrene hydroxylase activity. These effects were not decreased by thiolic compounds. The oxidation products of chloroform caused a general impairment of the monoxygenase system, probably related to the formation of protein aggregates with very high molecular weight. In the presence of physiological concentrations of GSH, the targets of aerobically-produced metabolite were lipids, and, to a smaller extent, p450. At low chloroform concentrations and/or in the presence of GSH, the most changes to microsomal structures seemed to be produced by the reductively-formed intermediates.